Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 10:30:09 2024-04-25 am EDT			5-day change	1st Jan Change
26.98 ^EUR	+0.05%		+2.69%	-19.88%

03:20pm	Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15	DP
02:05pm	Human rights activists complain to OECD about Bayer over glyphosate	DP

BAYER AG : Goldman Sachs reiterates its Buy rating

November 22, 2021 at 01:57 am EST

In a research note published by Keyur Parekh, Goldman Sachs advises its customers to buy the stock. The target price has been lifted and is now set at EUR 76 compared to EUR 71 before.

Latest news about Bayer AG

Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15	09:20am	DP
Human rights activists complain to OECD about Bayer over glyphosate	08:05am	DP
German cabinet approves restricted use of herbicide glyphosate	Apr. 24	RE
Dehoga: Challenging situation for company canteens	Apr. 23	DP
Germany's Evotec appoints Christian Wojczewski as CEO	Apr. 23	RE
Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple...	Apr. 23
Bayer: licensing agreement for biological insecticide	Apr. 23	CF
BAYER AG : Deutsche Bank reiterates its Neutral rating	Apr. 23	ZD
Bayer, AlphaBio Control Sign Exclusive License Deal for Biological Insecticide	Apr. 23	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
JPMorgan rates Bayer at 'Neutral' - Target 34 euros	Apr. 22	DP
BAYER AG : JP Morgan remains Neutral	Apr. 22	ZD
Bayer Signs Renewable Energy Purchase Deal for Six German Sites	Apr. 19	MT
Bayer: signs renewable energy supply contract	Apr. 19	CF
Capgemini: new platform implemented for Bayer	Apr. 19	CF
TV ratings: Bayer's Europa League success brings RTL many viewers	Apr. 19	DP
Bayer’s Investigational Gene Therapy for Heart Failure Gets US FDA Fast Track Designation	Apr. 18	MT
AskBio receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failure	Apr. 18	CI
Bayer: fast-track procedure in cardiology in the USA	Apr. 18	CF
Study: US companies outpace Europe and Asia in research spending	Apr. 18	DP
Stifel Cuts Bayer PT, Keeps Hold Rating	Apr. 17	MT
Sat.1 to show top match between FC Bayern and Stuttgart	Apr. 17	DP
Conti slumps to early November level after figures	Apr. 17	DP
BAYER : Stifel lowers its target price	Apr. 17	CF
Bayer: presents results on Parkinson's disease	Apr. 16	CF

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

2024-04-26 - Annual General Meeting

Related indices

EURO STOXX 50 , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : Another peer group tidy up

April 14, 2024 at 03:26 pm EDT

Bayer AG: Not out of the woods yet

March 06, 2024 at 10:46 am EST

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

26.97 EUR

Average target price

37.05 EUR

Spread / Average Target

+37.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-19.88%	28.31B
NOVO NORDISK A/S	+24.21%	562B
JOHNSON & JOHNSON	-6.39%	358B
MERCK & CO., INC.	+19.96%	322B
ABBVIE INC.	+7.35%	297B
ASTRAZENECA PLC	+13.32%	219B
NOVARTIS AG	+6.17%	199B
ROCHE HOLDING AG	-10.67%	196B
PFIZER, INC.	-10.87%	149B
AMGEN INC.	-6.88%	146B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

BAYER AG : Goldman Sachs reiterates its Buy rating

Latest news about Bayer AG

Chart Bayer AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bayer AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals